Assessment of dietary intake and its inflammatory potential in persons with pediatric-onset multiple sclerosis.

Objective: To compare diet and the modified dietary inflammatory index (mDII) between individuals with pediatric-onset multiple sclerosis (PoMS), monophasic acquired demyelinating syndromes (monoADS), and controls.
Methods: The association between diet, mDII, and disease status was examined in 131 individuals with PoMS/monoADS/controls (38/45/48) using logistic regression.
Results: The associations between diet and PoMS were modest, reaching significance for whole grain intake (adjusted odds ratio, aOR=0.964, 95 % confidence intervals, CI:0.934-0.995) but not mDII (aOR=1.20, 95 %CI:0.995-1.46) versus controls. No findings for monoADS reached significance versus controls.
Conclusions: Individuals with PoMS, but not monoADS, had lower dietary whole grain intake than controls.
Competing Interests: Declaration of competing interest Helen Tremlett has, in the last five years, received research support from the Canada Research Chair Program, the National Multiple Sclerosis Society, the Canadian Institutes of Health Research, the Multiple Sclerosis Society of Canada, the Multiple Sclerosis Scientific Research Foundation and the EDMUS Foundation (‘Fondation EDMUS contre la sclérose en plaques’). In addition, in the last five years, has had travel expenses or registration fees prepaid or reimbursed to present at CME conferences from the Consortium of MS Centres (2018, 2023), the Canadian Neurological Sciences Federation (2023), National MS Society (2018, 2022), ECTRIMS/ ACTRIMS (2017–2023), American Academy of Neurology (2019). Speaker honoraria are either declined or donated to an MS charity or to an unrestricted grant for use by HT's research group. Sama Bitarafan has nothing to declare. Feng Zhu was funded through research grants held by HT, including The Multiple Sclerosis Scientific and Research Foundation (PI: Tremlett, EGID: 2636). Charles N Bernstein is supported by the Bingham Chair in Gastroenterology. Dr. Bernstein has served on advisory Boards for AbbVie Canada, Amgen Canada, Bristol Myers Squibb Canada, Eli Lilly Canada, Ferring Canada, JAMP Pharmaceuticals, Pendopharm Canada, Roche Canada, Janssen Canada, Sandoz Canada, Takeda Canada, and Pfizer Canada; Consultant for Takeda; Educational grants from Abbvie Canada, Amgen Canada, Bristol Myers Squibb Canada, Eli Lilly Canada, Pfizer Canada, Takeda Canada, and Janssen Canada. Speaker's panel for Abbvie Canada, Janssen Canada, Pfizer Canada, and Takeda Canada. Received research funding from Abbvie Canada, Amgen Canada, Pfizer Canada, Sandoz Canada, and Takeda Canada. Ruth Ann Marrie receives research funding from: CIHR, Research Manitoba, MS Canada, Crohn's and Colitis Canada, National Multiple Sclerosis Society, CMSC, the Arthritis Society and the US Department of Defense, and is a co-investigator on studies receiving funding from Biogen Idec and Roche Canada. She holds the Waugh Family Chair in Multiple Sclerosis. Yinshan Zhao has nothing to declare. Emmanuelle Waubant has grants or contracts from NMSS, NIH, PCORI, Race to Erase MS, Octave, Payment or honoraria for lectures, presentations, speakers’ bureaus, manuscript writing or Gary Van Domselaar receives research funding from Canadian Institutes of Health Research, Multiple Sclerosis Society of Canada, Genome Canada, and the National Science and Engineering Research Council.
(Copyright © 2024 The Author(s). Published by Elsevier B.V. All rights reserved.)